Biomaterial-enabled multimodal therapy for endometrial cancer: Subtype-guided immuno-metabolic modulation and fertility-conscious regeneration
Source abstract
Abstract
Endometrial cancer (EC) encompasses various histological and molecular subtypes, each with unique immune, endocrine and metabolic characteristics, resulting in varying responses to treatment. Although immunotherapy, endocrine therapy and metabolic targeted therapy have broadened treatment options, the clinical efficacy varies due to subtype-specific drug resistance, systemic side effects, and the need for fertility preservation in young patients. This requires us to shift from simple combination therapy to a treatment model that integrates biological and subtype-specific information. The latest advancements in the field of biomaterials provide new approaches to achieve this integration. Tools such as nanocarriers and hydrogels can enable precise and localized drug delivery in the uterus, achieving controlled release based on specific tumor biological characteristics. For tumors with immune activity, they can locally deliver immune stimulants; for certain subtypes, they can directly provide continuous endocrine therapy within the tissue, avoiding systemic exposure. In cases of resistance, they can modify local metabolism to restore treatment sensitivity. Essentially, biomaterials act as intelligent interfaces, converting subtype-specific information into targeted treatment strategies. Specifically, biomaterial platforms can utilize endogenous tumor and tissue cues (pH, enzyme activity, redox state, or inflammatory signals) to trigger the on-demand release of immunomodulators, endocrine drugs, or metabolic regulators in the uterine microenvironment, thereby enhancing local efficacy while reducing systemic toxicity. Importantly, biomaterial-enabled strategies extend beyond tumor control by incorporating endometrial repair and regeneration into therapeutic design. By temporally decoupling antitumor intervention from regenerative signaling within a single platform, these approaches directly address the fertility-preserving imperative of EC management. This review systematically presents new multimodal therapeutic strategies for EC made possible by biomaterials, focusing on how spatial, temporal and biological programmability enables subtyped treatment, immunometabolic reprogramming and integrated regeneration. We explore design principles, translational challenges and clinical implications, proposing biomaterials as a paradigm for precision therapy focused on fertility preservation. It is important to note that this review systematically positions endometrial regeneration focused on preserving fertility as a fundamental therapeutic principle rather than as a complement downstream of tumor control, advocating its integration into comprehensive treatment plans from the start of subtyp-targeted therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Angiogenesis and VEGF in Cancer · Cancer Cells and Metastasis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (86)
Show source-provided references
1. Cancer statistics
2. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
3. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
4. Two pathogenetic types of endometrial carcinoma10.1016/0090-8258(83)90111-7 ↗
5. Molecular basis of endometriosis and endometrial cancer: current knowledge and future perspectives10.3390/ijms22179274 ↗
6. Locally advanced and metastatic endometrial cancer: current and emerging therapies10.1016/j.ctrv.2024.102790 ↗
7. Endometrial cancer10.1016/S0140-6736(22)00323-3 ↗
8. Recent advances in endometrial cancer prevention, early diagnosis and treatment10.3390/cancers16051028 ↗
9. Advances in the management of endometrial cancer
10. Endometrial cancer: rapid evidence review
11. Fertility-sparing treatments in endometrial cancer: a comprehensive review on efficacy, oncological outcomes, and reproductive potential10.3390/medicina61030471 ↗
12. Endometrial cancer: improving management among increasing incidence rates10.1016/j.ebiom.2024.105159 ↗
13. Imaging of endometrial cancer
14. Fertility sparing in endometrial cancer: where are we now?10.3390/cancers17010112 ↗
15. Immunotherapy in endometrial cancer10.1136/ijgc-2022-003675 ↗
16. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study10.1016/j.annonc.2022.05.519 ↗
17. Oaknin · J. Immunother. Cancer · 2022 · 1010.1136/jitc-2021-003777 ↗
18. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III Study 309/KEYNOTE-77510.1200/JCO.22.02152 ↗
19. Lenvatinib plus pembrolizumab for advanced endometrial cancer10.1056/NEJMoa2108330 ↗
20. FIGO staging of endometrial cancer: 202310.1002/ijgo.14923 ↗
21. Disease analysis working, Integrated genomic characterization of endometrial carcinoma10.1038/nature12113 ↗
22. Comprehensive review of endometrial cancer: new molecular and FIGO classification and recent treatment changes10.3390/jcm14041385 ↗
23. Molecular classification of endometrial cancer and its impact on therapy selection10.3390/ijms25115893 ↗
24. Implementation of the ProMisE classifier and validation of its prognostic impact in Brazilian endometrial carcinomas10.3389/fonc.2024.1503901 ↗
25. Molecular testing for endometrial cancer: an SGO clinical practice statement10.1016/j.ygyno.2022.10.024 ↗
26. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer10.1002/cncr.30496 ↗
27. Molecular profiling of endometrial cancer from TCGA to clinical practice10.6004/jnccn.2022.7096 ↗
28. Molecular subtypes of endometrial cancer: implications for adjuvant treatment strategies10.1002/ijgo.14969 ↗
29. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy10.1136/ijgc-2020-001822 ↗
30. New challenges in biomaterials10.1126/science.8134835 ↗
31. Endometrial regeneration and the role of the extracellular matrix: mechanisms, challenges, and future perspectives10.1016/j.tice.2025.103074 ↗
32. Nanocarrier drug delivery systems for gynecological cancer therapeutics10.1016/j.jconrel.2025.114028 ↗
33. Oral nano-formulations for endocrine therapy of endometrioid adenocarcinomas10.1016/j.biopha.2024.117328 ↗
34. Endocrine therapy for endometrial cancer: traditional approaches and novel targets10.3389/fonc.2025.1570011 ↗
35. Valabrega · Int. J. Gynecol. Cancer · 2025 · 35
36. Injectable Hydrogel-Based combination cancer immunotherapy for overcoming localized therapeutic efficacy10.3390/pharmaceutics14091908 ↗
37. Immunotherapy for endometrial cancer10.1007/s10147-024-02568-2 ↗
38. Facts and hopes in immunotherapy of endometrial cancer10.1158/1078-0432.CCR-21-1564 ↗
39. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer10.1080/14737140.2024.2367472 ↗
40. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer10.1016/j.annonc.2024.02.006 ↗
41. Immunotherapy in endometrial cancer: new scenarios on the horizon10.3802/jgo.2019.30.e46 ↗
42. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer10.1016/j.ygyno.2021.05.026 ↗
43. Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
44. Immunotherapy in ovarian, endometrial and cervical cancer: state of the art and future perspectives10.1016/j.ctrv.2017.07.008 ↗
45. Biomarkers and immunotherapy in endometrial cancer: mechanisms and clinical applications
46. Top advances of the year: immunotherapy in endometrial cancer10.1002/cncr.35417 ↗
47. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 Study10.1200/JCO.21.01874 ↗
48. Cancer Discov. · 2023 · 13 · 1030
49. TCGA molecular prognostic groups of endometrial carcinoma: current knowledge and future perspectives10.3390/ijms231911684 ↗
50. Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study10.3389/fimmu.2022.1035616 ↗
51. Robust and sustained STING pathway activation via Hydrogel-Based in situ vaccination for cancer immunotherapy10.1021/acsnano.3c12337 ↗
52. Precision endocrine therapy in endometrial cancer: has its time finally come?10.1158/1078-0432.CCR-24-3905 ↗
53. Endocrine therapy in endometrial cancer: an old dog with new tricks10.1016/j.ygyno.2018.12.018 ↗
54. Small molecule targeted therapies for endometrial cancer: progress, challenges, and opportunities10.1039/D4MD00089G ↗
55. The next-generation oral selective Estrogen receptor degrader Camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance10.1158/0008-5472.CAN-23-0694 ↗
56. Fucoxanthin prevents cell growth and induces apoptosis in endometrial cancer HEC-1A cells by the inhibition of the PI3K/Akt/mTOR pathway10.1002/jbt.23027 ↗
57. The interplay of sex steroid hormones and microRNAs in endometrial cancer: current understanding and future directions10.3389/fendo.2023.1166948 ↗
58. Metabolic syndrome as a risk factor of endometrial cancer: a nationwide population-based cohort Study of 2.8 million women in South Korea10.3389/fonc.2022.872995 ↗
59. The role of "Metabolic Instability" as a new risk criterion in the pathogenesis of endometrial cancer10.3390/cancers17233840 ↗
60. Metabolic syndrome and survival outcomes in endometrial cancer
61. Insulin resistance: the increased risk of cancers10.3390/curroncol31020075 ↗
62. Nanocarrier-based targeting of metabolic pathways for endometrial cancer: status and future perspectives10.1016/j.biopha.2023.115348 ↗
63. Mechanisms of regeneration and fibrosis in the endometrium10.1146/annurev-cellbio-011723-021442 ↗
64. Role of HOXA10 in pathologies of the endometrium10.1007/s11154-024-09923-8 ↗
65. Upregulation HOXA10 homeobox gene in endometrial cancer: role in cell cycle regulation10.1007/s12032-014-0052-2 ↗
66. Insights from genomic studies on the role of sex steroids in the aetiology of endometriosis10.1530/RAF-21-0078 ↗
67. The effect of endometrial polyp and myoma Uteri on fertility-related genes in the endometrium10.1007/s43032-025-01802-0 ↗
68. Loss of HOXA10 causes endometrial hyperplasia progressing to endometrial cancer10.1530/JME-22-0051 ↗
69. Impaired fertility in adenomyosis: a murine model reveals endometrial receptivity and progesterone resistance imbalances10.1530/REP-24-0019 ↗
70. Expression of EMT-related genes in lymph node metastasis in endometrial cancer: a TCGA-based study10.1186/s12957-023-02893-2 ↗
71. Endometriosis and cancer risk10.1097/CEJ.0000000000000965 ↗
72. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms10.1002/1878-0261.12772 ↗
73. Exploration of eMSCs with HA-GEL system in repairing damaged endometrium after endometrial cancer with fertility-sparing treatment10.1007/s00441-023-03831-0 ↗
74. Thermosensitive hydrogel as a sustained release carrier for mesenchymal stem cell-derived extracellular vesicles in the treatment of intrauterine adhesion10.1186/s12951-024-02780-2 ↗
75. Ru single-atom nanozymes targeting ROS-ferroptosis pathways for enhanced endometrial regeneration in intrauterine adhesion therapy10.1016/j.biomaterials.2024.122923 ↗
76. 3D printed gelatin/PTMC core/shell scaffolds with NIR laser-tuned drug/biomolecule release for cancer therapy and uterine regeneration
77. Effects of estradiol on VEGF and bFGF by Akt in endometrial cancer cells are mediated through the NF-κB pathway10.3892/or.2016.4888 ↗
78. Testosterone, sex hormone-binding globulin, insulin-like growth factor-1 and endometrial cancer risk: observational and Mendelian randomization analyses10.1038/s41416-021-01518-3 ↗
79. Therapeutic roles of platelet-rich plasma to restore female reproductive and endocrine dysfunction
80. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer10.1080/13543784.2018.1558202 ↗
81. Local delivery of platelet-derived factors mitigates ischemia and preserves ovarian function through angiogenic modulation: a personalized regenerative strategy for fertility preservation10.1016/j.biomaterials.2024.122768 ↗
82. Advances in nanomedicine and biomaterials for endometrial regeneration: a comprehensive review10.2147/IJN.S473259 ↗
83. 3D bioprinting and artificial intelligence for tumor microenvironment modeling: a scoping review of models, methods, and integration pathways10.1021/acs.molpharmaceut.5c01062 ↗
84. Advances in hybrid hydrogel design for biomedical applications: innovations in drug delivery and tissue engineering for gynecological cancers10.1007/s10565-025-10064-0 ↗
85. Real-world treatment patterns and clinical outcomes in patients with advanced or recurrent endometrial cancer re-challenged with platinum-based chemotherapy in Europe10.1016/j.ijgc.2025.101658 ↗
86. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: a real-world endometrial cancer molecularly targeted therapy consortium cohort study10.1016/j.ygyno.2025.02.013 ↗